Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Financing Activities: 2016-2025

Historic Cash from Financing Activities for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $8.3 million.

  • UroGen Pharma's Cash from Financing Activities fell 79.11% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 95.54%. This contributed to the annual value of $194.6 million for FY2024, which is 66.44% up from last year.
  • Latest data reveals that UroGen Pharma reported Cash from Financing Activities of $8.3 million as of Q3 2025, which was up 2,694.59% from $296,000 recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Cash from Financing Activities peaked at $116.1 million during Q3 2023, and registered a low of -$168,000 during Q3 2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was $671,000 (2023), whereas its average is $29.1 million.
  • Per our database at Business Quant, UroGen Pharma's Cash from Financing Activities plummeted by 375.41% in 2021 and then skyrocketed by 1,768,450.00% in 2022.
  • UroGen Pharma's Cash from Financing Activities (Quarterly) stood at -$32,000 in 2021, then surged by 79,375.00% to $25.4 million in 2022, then plummeted by 99.84% to $40,000 in 2023, then soared by 77.50% to $71,000 in 2024, then plummeted by 79.11% to $8.3 million in 2025.
  • Its last three reported values are $8.3 million in Q3 2025, $296,000 for Q2 2025, and $34,000 during Q1 2025.